Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofloxacin + ornidazole + itraconazole + clobetasol propionate
- Development stage
- Preclinical
- Lead developer
- Amvia Biotech
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ITVIA PLUS is a topical combination cream developed by Amvia Biotech for the treatment of mixed skin infections. It contains four active pharmaceutical ingredients: ofloxacin, a fluoroquinolone antibiotic; ornidazole, a nitroimidazole with antiprotozoal and antibacterial properties; itraconazole, a triazole antifungal; and clobetasol propionate, a high-potency corticosteroid. This formulation is designed to address superficial fungal infections complicated by secondary bacterial or protozoal infections, as well as inflammatory dermatoses. Ofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, while ornidazole causes DNA strand breakage in anaerobic organisms. Itraconazole inhibits fungal ergosterol synthesis by targeting lanosterol 14-alpha-demethylase, and clobetasol propionate provides potent anti-inflammatory, antipruritic, and vasoconstrictive effects through glucocorticoid receptor activation.
- Brand names
- ITVIA PLUS
02
Targets
Topo IV (Bacterial Topoisomerase IV)CYP51A1 (Sterol 14α-demethylase)Microbial DNA after nitro-radical activationGR (Glucocorticoid receptor)DNA gyrase
Beyond the preview
Go deeper on ofloxacin + ornidazole + itraconazole + clobetasol propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofloxacin + ornidazole + itraconazole + clobetasol propionate.